Verona Pharma (NASDAQ:VRNA - Get Free Report) had its price objective hoisted by investment analysts at HC Wainwright from $60.00 to $75.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price suggests a potential upside of 11.11% from the stock's previous close. HC Wainwright also issued estimates for Verona Pharma's Q1 2026 earnings at $0.16 EPS and Q2 2026 earnings at $0.40 EPS.
A number of other equities analysts have also commented on the stock. Roth Capital upgraded shares of Verona Pharma to a "strong-buy" rating in a research report on Friday, January 10th. Canaccord Genuity Group boosted their price target on shares of Verona Pharma from $44.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday, February 12th. Roth Mkm initiated coverage on shares of Verona Pharma in a report on Friday, January 10th. They issued a "buy" rating and a $68.00 price target on the stock. Wells Fargo & Company lifted their price objective on Verona Pharma from $64.00 to $74.00 and gave the company an "overweight" rating in a research note on Wednesday, January 8th. Finally, Truist Financial restated a "buy" rating and issued a $57.00 target price (up from $44.00) on shares of Verona Pharma in a research note on Wednesday, January 8th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $66.83.
Check Out Our Latest Stock Report on VRNA
Verona Pharma Stock Performance
Shares of NASDAQ VRNA traded up $1.53 during mid-day trading on Friday, hitting $67.50. The company had a trading volume of 1,202,328 shares, compared to its average volume of 1,568,357. The stock's 50-day moving average price is $55.46 and its 200-day moving average price is $41.44. The company has a market capitalization of $5.43 billion, a price-to-earnings ratio of -35.16 and a beta of 0.41. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. Verona Pharma has a 1 year low of $11.39 and a 1 year high of $70.40.
Insider Activity at Verona Pharma
In other news, CFO Mark W. Hahn sold 183,728 shares of the firm's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $5.01, for a total transaction of $920,477.28. Following the transaction, the chief financial officer now directly owns 13,293,736 shares of the company's stock, valued at approximately $66,601,617.36. This trade represents a 1.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David Zaccardelli sold 162,800 shares of the business's stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $5.01, for a total value of $815,628.00. Following the completion of the sale, the chief executive officer now directly owns 14,204,752 shares of the company's stock, valued at approximately $71,165,807.52. This trade represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 472,320 shares of company stock valued at $2,365,065. Corporate insiders own 4.80% of the company's stock.
Hedge Funds Weigh In On Verona Pharma
Large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Verona Pharma by 25.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company's stock valued at $75,000 after purchasing an additional 529 shares during the period. Diversify Advisory Services LLC bought a new position in Verona Pharma in the third quarter worth about $169,000. Diversify Wealth Management LLC bought a new stake in Verona Pharma during the 3rd quarter valued at approximately $611,000. Rice Hall James & Associates LLC grew its holdings in shares of Verona Pharma by 4.8% during the 3rd quarter. Rice Hall James & Associates LLC now owns 985,076 shares of the company's stock worth $28,341,000 after acquiring an additional 45,500 shares during the period. Finally, Rosalind Advisors Inc. raised its position in shares of Verona Pharma by 10.0% in the 3rd quarter. Rosalind Advisors Inc. now owns 275,000 shares of the company's stock worth $7,912,000 after acquiring an additional 25,000 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.
About Verona Pharma
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Recommended Stories
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
